PRLD Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 23.51%, SMA50 24.95%, SMA200 97.41%). The stock’s 14-day RSI is 60.99 (firm momentum), while the ATR of 0.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -31.99% below its high and over 370.41% above its low. Average 10-day trading volume of 438.53 thousand shares is in line with the 3-month average of 438.92 thousand, indicating normal recent market interest.

Prelude Therapeutics Incorporated generated EPS of -$1.61 over the past year. Five-year average earnings growth is -21.61%. The latest quarter delivered EPS of -$0.13. The next quarter is forecast at -$0.03. Next year's EPS is expected at $5.43. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $3.00. The high target offers 95.65% upside. The low target suggests -34.78% downside. The mean target is $6.50. This offers 41.3% upside. Prelude Therapeutics Incorporated earnings surprise history is frequent misses against expectations. The quarter that ended May 12, 2026, missed forecasts by -51.85%. The prior quarter beat by -39.39%. Over the last six quarters, Apple has recorded several small beats. These include -22.45% in March 10, 2025.

Prelude Therapeutics Incorporated has 64.92 million shares outstanding. The public float is 27.59 million shares, elevated short interest at 13.06% of float. This equals 3.29 million shares. The short ratio is 5.75 days. Institutional investors hold 75.2% of the float. Insiders own 13.8%. Vaddi Krishna holds 2.00 million shares, BAKER BROS. ADVISORS LP has 1.68 million shares and ORBIMED ADVISORS LLC has 1.13 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Prelude Therapeutics Incorporated last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.06. This means the shares are trading above this model’s fair value.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) closed at $4.60 USD, losing -$0.45 (-8.91%) from the previous close of $5.05. The stock is currently mid-range between its 52-week high and low $0.75 and $5.69. With a market capitalization of about $261.89 million, Prelude Therapeutics Incorporated is classified as a micro-cap and shows market-like volatility (beta ~0.95). Key stats such as the average daily volume over the past year has been around 452.39 thousand shares, volume is running light vs its 52-week average. Headquartered in Wilmington, DE, Prelude Therapeutics Incorporated operates in the Healthcare sector and the Biotechnology industry. Led by CEO Krishna Vaddi, the company employs approximately 79 people and listed since September 25, 2020. Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) shares are down -36.55% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Prelude Therapeutics Incorporated trading at a premium to the broader market with a P/E of -4.49. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.00, suggesting 269.57% upside. Our AI forecast model points to short-term weakness (-5.0% over two weeks), a medium-term rise (60.0% over three months), and a longer-term gain (637.39% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Prelude Therapeutics Incorporated stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.0%, with price expected at $4.37 by August 13, 2026, within a range of $4.03 to $4.69 3-Month Outlook: Projected rise of 60.0%, reaching $7.36 by October 28, 2026, with a range of $7.24 to $7.50. 1-Year Outlook: Projected gain of 637.39%, with price at $33.92 by July 30, 2027, within a range of $35.78 to $36.89.

Prelude Therapeutics Incorporated trades at a P/E ratio of -4.49, slightly below the S&P 500 average, with a price-to-sales ratio of 16.19 and a price-to-book ratio of 6.52 trading at moderately above to book value. The P/FCF stands at -6.18, also below market averages.